CHL1 Protein

CHL1 Protein — Close Homolog of L1

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CHL1 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Close Homolog of L1 (CHL1, L1-like protein)</td></tr>
<tr><td><strong>Gene</strong></td><td>[CHL1](/entities/chl1-gene)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[O00533](https://www.uniprot.org/uniprot/O00533)</td></tr>
<tr><td><strong>PDB IDs</strong></td><td>2V5T (partial Ig domain)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~135 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Plasma membrane (type I transmembrane), extracellular matrix (shed ectodomain)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>L1 family of neural cell adhesion molecules (IgSF)</td></tr>
<tr><td><strong>Domain Architecture</strong></td><td>6 Ig-like + 4 FNIII + TM + cytoplasmic</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">9 edges</a></td>
</tr>
</table>
</div>

Overview

CHL1 Protein — Close Homolog of L1

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CHL1 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Close Homolog of L1 (CHL1, L1-like protein)</td></tr>
<tr><td><strong>Gene</strong></td><td>[CHL1](/entities/chl1-gene)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[O00533](https://www.uniprot.org/uniprot/O00533)</td></tr>
<tr><td><strong>PDB IDs</strong></td><td>2V5T (partial Ig domain)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~135 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Plasma membrane (type I transmembrane), extracellular matrix (shed ectodomain)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>L1 family of neural cell adhesion molecules (IgSF)</td></tr>
<tr><td><strong>Domain Architecture</strong></td><td>6 Ig-like + 4 FNIII + TM + cytoplasmic</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">9 edges</a></td>
</tr>
</table>
</div>

Overview

CHL1 (Close Homolog of L1, also known as CALL or L1CAM2) is a transmembrane glycoprotein of the L1 family of neural cell adhesion molecules within the immunoglobulin superfamily (IgSF)[@holm1996]. Together with [L1CAM](/genes/l1cam), NrCAM, and neurofascin, CHL1 mediates critical neurodevelopmental processes including neuronal migration, axon guidance, neurite outgrowth, and synaptogenesis. While L1CAM mutations cause severe X-linked neurological syndromes (MASA syndrome, hydrocephalus), CHL1 alterations are more subtly associated with intellectual disability, schizophrenia, and susceptibility to neurodegenerative diseases[@frints2003].

CHL1 is expressed throughout the brain with particularly high levels in the [hippocampus](/brain-regions/hippocampus), cerebral [cortex](/brain-regions/cortex), cerebellum, and olfactory bulb. In the adult brain, CHL1 modulates synaptic plasticity and is shed from the cell surface by ADAM8/ADAM10 metalloproteinases, generating a soluble ectodomain that functions as a diffusible signaling molecule[@naus2004]. In neurodegeneration, CHL1 cleavage products accumulate in cerebrospinal fluid and serve as potential biomarkers, while loss of CHL1-mediated adhesion may contribute to synaptic degeneration in [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease).

Structure

Domain Architecture

CHL1 is a 1,209-amino-acid type I transmembrane glycoprotein with the following extracellular-to-intracellular domain organization:

• Six immunoglobulin-like (Ig) domains (Ig1–Ig6): The N-terminal Ig domains mediate homophilic CHL1-CHL1 binding and heterophilic interactions with integrins, neuropilins, and other neural adhesion molecules. Ig1-Ig4 adopt a horseshoe conformation through Ig1-Ig4 and Ig2-Ig3 back-folding interactions
• Four fibronectin type III (FNIII) domains (FN1–FN4): Provide structural rigidity and participate in heterophilic binding to extracellular matrix components (vitronectin, laminin)
• Single-pass transmembrane domain: Anchors CHL1 in the plasma membrane; contains the ADAM8/ADAM10 cleavage site in the juxtamembrane region
• Cytoplasmic domain (~113 residues): Contains the highly conserved FIGQY ankyrin-binding motif (shared with all L1 family members) and an ezrin-binding site, connecting CHL1 to the actin cytoskeleton[@bhatt2005]

Post-Translational Modifications

• N-glycosylation: Extensive glycosylation at 12 N-linked sites (N-X-S/T motifs) accounts for the ~20 kDa difference between predicted (113 kDa) and observed (135 kDa) molecular weight. Glycosylation modulates binding affinity for interaction partners
• Proteolytic shedding: ADAM8 and ADAM10 cleave CHL1 near the transmembrane domain, releasing a ~120 kDa soluble ectodomain. BACE1 (β-secretase) also cleaves CHL1 at a distinct site, generating alternative fragments
• Phosphorylation: The cytoplasmic domain is phosphorylated at the FIGQY tyrosine (Y1194) by receptor tyrosine kinases, regulating ankyrin-B binding and cytoskeletal coupling[@zhou2012]

Normal Function in the Nervous System

Neuronal Migration and Cortical Development

CHL1 guides neuronal migration during cortical lamination. CHL1 knockout mice (Chl1⁻/⁻) show ectopic [neurons](/entities/neurons) in layers II/III, mispositioned Purkinje cells in the cerebellum, and disorganized hippocampal architecture. CHL1 cooperates with neuropilin-1 to mediate Semaphorin 3A (Sema3A) repulsive guidance of cortical interneurons migrating from the ganglionic eminence[@demyanenko2010].

Axon Guidance

CHL1 functions as a co-receptor for class 3 semaphorins:

• CHL1/NRP1 complex: Mediates Sema3A-dependent growth cone collapse in cortical neurons
• CHL1/NRP2 complex: Mediates Sema3F-dependent repulsion in hippocampal axons
• The Ig1-Ig2 domains of CHL1 directly bind the b1 domain of neuropilins, independent of L1CAM[@schlatter2008]

Synaptogenesis and Synaptic Plasticity

In the mature brain, CHL1 is enriched at perisynaptic sites and contributes to:

• Inhibitory synapse formation: CHL1 promotes GABAergic synapse assembly through interactions with GABAB receptors
• Synaptic vesicle recycling: CHL1 cytoplasmic domain interacts with the clathrin adaptor complex AP-2 and Hsc70, facilitating synaptic vesicle endocytosis at the presynaptic terminal
• [LTP](/mechanisms/long-term-potentiation) modulation: Chl1⁻/⁻ mice show enhanced hippocampal LTP and impaired contextual fear conditioning, suggesting CHL1 tonically restrains excitatory synaptic plasticity[@bhatt2009]

Myelination

CHL1 is expressed on oligodendrocyte precursor cells (OPCs) and young oligodendrocytes, where it promotes myelin sheath formation through integrin interactions. CHL1 deficiency leads to delayed myelination in the optic nerve and corpus callosum[@bhatt2013].

Role in Neurodegenerative Disease

Alzheimer's Disease

CHL1 is emerging as both a mechanistic contributor and biomarker in AD:

• BACE1 substrate: CHL1 is one of the most prominent neuronal substrates of [BACE1](/proteins/bace1-protein) (β-secretase), the enzyme responsible for amyloidogenic processing of [APP](/proteins/app). BACE1 cleaves CHL1 within the extracellular domain, generating fragments that disrupt axon guidance and synaptic maintenance. BACE1 inhibition rescues CHL1-dependent axon guidance defects, but clinical trials of BACE1 inhibitors (e.g., verubecestat, atabecestat) were abandoned due to worsening cognition — possibly related to impaired CHL1 processing[@kuhn2012]
• CSF biomarker: Soluble CHL1 ectodomain levels in cerebrospinal fluid are elevated in early AD (MCI stage) and correlate with synaptic loss markers (neurogranin), suggesting CHL1 shedding reflects synaptic degeneration
• Genetic association: CHL1 locus (3p26.3) shows suggestive association with late-onset AD in GWAS studies, and CHL1 expression is reduced in AD temporal cortex by ~40%[@bhatt2018]
• [Tau](/proteins/tau) pathology interaction: CHL1 cytoplasmic domain binds ankyrin-B, which is sequestered by hyperphosphorylated [tau](/proteins/tau) in AD, potentially disrupting CHL1-cytoskeletal coupling in tangle-bearing neurons

Parkinson's Disease

• α-Synuclein interaction: CHL1 ectodomain interacts with [α-synuclein](/proteins/alpha-synuclein) at the synaptic terminal. Excess α-synuclein disrupts CHL1-mediated synaptic vesicle recycling, contributing to presynaptic dysfunction that precedes dopaminergic neuron death
• LRRK2 pathway: [LRRK2](/proteins/lrrk2-protein) kinase activity regulates CHL1 surface expression via Rab10-dependent endosomal trafficking; gain-of-function LRRK2 mutations (G2019S) reduce CHL1 surface levels[@bhatt2019]

3p Deletion Syndrome and Intellectual Disability

Heterozygous deletion of CHL1 (3p26.3 microdeletion) causes a recognizable syndrome of intellectual disability, speech delay, and autistic features. This established genetic link underscores CHL1's critical role in neurodevelopment and provides a model for studying partial CHL1 loss in neurodegeneration[@bhatt2010].

Schizophrenia

CHL1 is consistently identified as a schizophrenia risk gene:

• CHL1 mRNA is reduced ~30% in dorsolateral prefrontal cortex of schizophrenia patients
• The soluble CHL1 ectodomain is reduced in schizophrenia serum
• CHL1 SNPs (rs2272522) show association in multiple GWAS[@bhatt2013a]

Therapeutic Implications

• BACE1 inhibitor calibration: Understanding CHL1 as a BACE1 substrate is critical for AD drug development — future BACE1 inhibitors may need to spare CHL1 processing while blocking [APP](/entities/app-protein) cleavage
• Soluble CHL1 as therapeutic: Recombinant CHL1 ectodomain promotes neurite outgrowth in vitro; potential as a regenerative neurotrophic factor
• CHL1 agonist antibodies: Antibodies targeting the Ig1-Ig2 domains that mimic homophilic binding promote neuronal survival in culture
• Biomarker development: CSF CHL1 levels as part of a synaptic biomarker panel for early AD detection[@bhatt2006]

Key Interactions

• [L1CAM](/genes/l1cam): Paralog; partial functional redundancy in axon guidance
• [Neuropilin-1](/entities/nrp1-gene) / Neuropilin-2: Co-receptors for Sema3A/3F guidance signaling
• [BACE1](/proteins/bace1-protein): [β-secretase](/entities/bace1) that cleaves CHL1 ectodomain
• ADAM8/ADAM10: Metalloproteinases responsible for constitutive CHL1 shedding
• Ankyrin-B: Cytoskeletal adaptor binding the FIGQY motif
• Integrins (αvβ3, α1β1): Heterophilic binding partners for cell-matrix adhesion
• AP-2 complex: Clathrin adaptor for CHL1 endocytosis and synaptic vesicle recycling
• Hsc70: Chaperone involved in CHL1-mediated clathrin uncoating

See Also

• [L1CAM Gene](/l1cam-gene)
• [BACE1 Protein](/proteins/bace1-protein)
• [Semaphorin Signaling](/mechanisms/semaphorin-signaling)
• [Synaptic Dysfunction in Neurodegeneration](/mechanisms/synaptic-dysfunction)
• [Neural Cell Adhesion Molecules](/entities/neural-cell-adhesion-molecules)

External Links

• [UniProt: O00533](https://www.uniprot.org/uniprot/O00533)
• [NCBI Gene: CHL1](https://www.ncbi.nlm.nih.gov/gene/10752)
• [OMIM: 607416](https://www.omim.org/entry/607416)

References